ArticleCancer research communications2025
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials.
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study.The oncologist · 2025Trial
- Long non-coding RNAs in the crosstalk between diabetes and colorectal cancer: molecular mechanisms and endocrine pathways.Frontiers in molecular biosciences · 2026Review
- Clinical outcomes of treatments for patients with refractory metastatic colorectal cancer: a systematic literature review and network meta-analysis.Therapeutic advances in medical oncology · 2026Article
- Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial.ESMO gastrointestinal oncology · 2025Article
- Stanniocalcin Protein Expression in Female Reproductive Organs: Literature Review and Public Cancer Database Analysis.Endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
abstractBiomarkers for antiangiogenic drugs in chemorefractory metastatic colorectal cancer (mCRC) are lacking. We investigated the relationship between stanniocalcin 1 (STC1) and outcomes in patients treated with regorafenib in the TEXCAN and CORRECT trials. Baseline plasma STC1 protein levels were measured by ELISA from patients with chemorefractory mCRC enrolled in TEXCAN (regorafenib n = 48) and CORRECT (placebo n = 211; regorafenib n = 435). The relationship between STC1 levels and overall survival (OS) was assessed using a Cox proportional hazards model. The median STC1 value was increased in patients with chemorefractory mCRC (1,211 pg/mL) compared with previously untreated patients (215 pg/mL). Using an optimized cut-off, STC1 was prognostic for OS [HR = 2.12, 95% confidence interval (CI), 1.79–2.50; P < 0.001], with a median OS of 7.63 months in the STC1-low group (<1,436.87 pg/mL; n = 400) and 3.81 months in the STC1-high group (≥1,436.87 pg/mL; n = 246). The interaction P value of lactate dehydrogenase and treatment revealed no predictive effect of lactate dehydrogenase levels on OS in terms of regorafenib (P = 0.598). A predictive analysis suggested a significant association between STC1 and regorafenib for OS (interaction P = 0.049). The median OS with regorafenib versus placebo was 8.32 versus 6.54 months in the STC1-low group (HR = 0.83, 95% CI, 0.66–1.03; P = 0.087) and 4.41 versus 3.09 months in the STC1-high group (HR = 0.64, 95% CI, 0.49–0.84; P = 0.001). Altogether, high STC1 protein levels have a predictive potential to characterize a population of patients with chemorefractory mCRC and poor prognosis in whom regorafenib has an increased level of efficacy. SIGNIFICANCE: STC1 is a protein secreted by intratumor endothelial cells in which plasma concentrations increase in patients with chemorefractory mCRC. Based on analyses of patients with refractory mCRC in the TEXCAN and CORRECT trials, we found that STC1 plasma levels had a prognostic role for OS, with high levels associated with poor outcome. A predictive role for baseline STC1 levels was pointed out for regorafenib efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.